Read our latest updates & insights

On 18 August 2026, Korea Biomedical Review reported that Sam Chun Dang (SCD) signed a settlement agreement with Regeneron and Bayer to resolve all patent disputes in Europe, Korea and Japan involving SCD411, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2 mg.  ...

On 17 August 2026, Sandoz and Shanghai Henlius Biotech announced that they have entered into a major development, manufacturing and commercialisation collaboration agreement, covering up to 10 biosimilars (including monoclonal antibodies and/or antibody-drug conjugates).

On 13 August 2026, Celltrion announced that the FDA has granted fast track designation to CT-P73, an antibody drug conjugate (ADC) for the treatment of patients with recurrent and metastatic cervical cancer who have previously received platinum based chemotherapy.

Fa...

On 13 August 2026, Bayer announced that China’s National Medical Products Administration (NMPA) has accepted for review its application for Eylea® (aflibercept) 8 mg (114.3 mg/ml solution) for injection) for the treatment of macular oedma following retinal vein occlusion (R...

On 11 August 2026, Mabwell announced that it has entered into licensing and commercialisation agreements with unidentified partners in the Philippines, Vietnam and Malaysia for 9MW0813, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2mg.

Under the terms of the ...

On 10 August 2026, Samsung Bioepis announced that it has applied to Korea’s Ministry of Food and Drug Safety for approval of SB27, biosimilar to MSD’s Keytruda® (pembrolizumab).  According to Samsung Bioepis, this application puts it ahead of competitor pembrolizumab biosim...

On 10 August 2026, Samsung Bioepis announced the European launch of Opuviz®/SB15 (aflibercept), biosimilar to Regeneron/Bayer’s Eylea® 2mg in a pre-filled syringe (PFS) presentation (40 mg/mL).  Opuviz® was the third aflibercept biosimilar to be approved in the EU in Novemb...

On 10 August 2026, Amneal Pharmaceuticals announced the completion of its acquisition of Kashiv BioSciences.  This follows the companies entering into a definitive agreement in April 2026, and is in line with their expectations of a H2/2026 closing.

The acquisition c...